• ACVC Callout
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Novartis to develop transdermal insulin

April 1, 2010

Melbourne, Australia -- Novartis Animal Health signed an agreement March 31 with Australian pharmaceutical company Phosphagenics Ltd. to develop a transdermal insulin delivery system for pets.

Melbourne, Australia

-- Novartis Animal Health signed an agreement March 31 with Australian pharmaceutical company Phosphagenics Ltd. to develop a transdermal insulin delivery system for pets.

The formulation and potential product is still in the planning stages. But a Phosphagenics spokesperson touted the potential benefits of trandermal-applied insulin: more user-friendly than injections, improving client compliance and the use of insulin for companion animals.

Novartis will pay to develop the product and compensate Phosphagenics with additional royalties and milestone payments if the product is released in the market.

Related Content:

Breaking News
Veterinarians reflect on Queen Elizabeth’s legacy and love of animals
Veterinarians reflect on Queen Elizabeth’s legacy and love of animals
Updates on the monkeypox virus
Updates on the monkeypox virus
Veterinary hospital office manager sentenced for stealing opioids from clinic
Veterinary hospital office manager sentenced for stealing opioids from clinic

Latest News

3 Must-listens for International Podcast Day

GlobalVetLink adds Equine Rabies Vaccination Certificates to its compliance platform

Celebrating through education

Joe Bailey appointed new chief executive for Humanimal Trust

View More Latest News